Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
By targeting both GLP-1 and GIP receptors simultaneously, tirzepatide appears to produce a more powerful combined effect on appetite suppression and metabolic function
In ESSENCE, 37% of people treated with semaglutide saw an improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo at the 72-week timepoint
Prescription drugs may not be ideal for ongoing use due to high cost, increasing side effects over time, and uncertain long-term safety for certain individuals
Aronne, D
It rose gradually during the dose-escalation phase, peaked around week 24, and then declined at weeks 36 and 48 even though participants continued taking the same dose
